
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Alpelisib for the treatment of PIK3CA-mutated HR/HER2- advanced breast cancer in combination with fulvestrant; It is the first drug to target PIK3CA mutations, which can effectivel···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:285
Alpelisib, approved in combination with fulvestrant in 2019 for the treatment of HR/HER2- breast cancer, specifically PIK3CA mutation cases; By inhibiting the PI3K pathway, it can ···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:311
Anamorelin is a ghrelin receptor agonist used to treat cancer cachexia and significantly improve patients' quality of life by increasing appetite and weight.What are Anamorelin···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:254
Anamorelin is currently the only effective therapeutic drug that promotes appetite and muscle growth in cancer dyscrasia patients by mimicking the action of ghrelin.What are the An···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:250
Koselugois a precision small molecule MEK blocker engineered for specific tumors, particularly in the treatment of neurofibromatosis (NF1), demonstrating superior performance.Does ···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:280
Anamorelin is a ghrelin receptor agonist launched in Japan that brings a new treatment option to cancer cachexia patients by increasing appetite and weight.What drugs does Anamorel···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:275
Koselugois a precision small molecule MEK inhibitor designed for specific tumor types, especially in the treatment of neurofibromatosis (NF1).Is Koselugoeffective?The therapeutic e···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:341
Koselugo is a carefully developed small molecule MEK blocker (also known as a mitogen activation inhibitor) whose core medical strategy focuses on precisely targeting targeted inte···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:328
As the world's first drug specifically for the treatment of cachexia, Anamorelin helps patients restore their appetite and increase weight and muscle mass by stimulating ghreli···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:249
Anamorelin is a drug that mimics the function of ghrelin in the human body, which can increase appetite and increase muscle mass, and is used to improve weight and appetite problem···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:244
Koselugo is a carefully developed small molecule MEK inhibitor (also known as a Schengen-activated antagonist) with a focus on precisely targeted therapies for specific tumor types···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:292
Koselugo is a class of finely designed small molecule MEK blockers (also known as mitogen activation inhibitors), and its core therapeutic strategy is targeted therapy for specific···【more】
Article source:Captain MedicineRelease date:2024-08-22Recommended:289
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2652025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4862024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2712025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2822025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3052025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2662025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2452025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: